Literature DB >> 23171834

A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.

Satoshi Morishige1, Eijiro Oku, Yuka Takata, Yoshizo Kimura, Fumiko Arakawa, Ritsuko Seki, Rie Imamura, Koichi Osaki, Michitoshi Hashiguchi, Kazuaki Yakushiji, Shinichi Mizuno, Koji Yoshimoto, Koji Nagafuji, Koichi Ohshima, Takashi Okamura.   

Abstract

The 8p11 myeloproliferative syndrome is a rare neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 (FGFR1) gene located at chromosome 8p11-12. FGFR1 encodes a transmembrane receptor tyrosine kinase. The resultant fusion proteins are constitutively active tyrosine kinases that drive the proliferation of hematopoietic cells, whose uncontrolled growth can present as a myeloproliferative neoplasm. We report here the case of a 50-year-old man harboring the t(8;22)(p12;q11) chromosomal translocation in cells from both bone marrow and lymph nodes. He presented with acute leukemia and lymphoma with trilineage features. A novel mRNA in-frame fusion between exon 4 of the breakpoint cluster region (BCR) gene at chromosome 22q11 and exon 9 of FGFR1 gene on chromosome 8p11-12 was identified by reverse transcription polymerase chain reaction analysis and was confirmed by DNA sequencing. Because the patient was refractory to chemotherapy, cord blood transplantation was performed in progressive disease. It resulted in a successful outcome in which cytogenetic complete remission has been maintained for 2 years till date.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23171834     DOI: 10.1159/000341289

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  9 in total

1.  Reply to the letter by Yang et al. RE: acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Yonggoo Kim; Hyeyoung Lee; Myungshin Kim
Journal:  Int J Hematol       Date:  2013-06-05       Impact factor: 2.490

2.  8p11 Myeloproliferative syndrome with t(8;22)(p11;q11): A case report.

Authors:  Jing Jing Liu; Li Meng
Journal:  Exp Ther Med       Date:  2018-06-20       Impact factor: 2.447

3.  Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

Authors:  M S Khodadoust; B Luo; B C Medeiros; R C Johnson; M D Ewalt; A S Schalkwyk; C D Bangs; A M Cherry; S Arai; D A Arber; J L Zehnder; J Gotlib
Journal:  Leukemia       Date:  2015-06-09       Impact factor: 11.528

Review 4.  Acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Hyeyoung Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Byung-Sik Cho; Hee-Je Kim
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490

5.  Early lesions of follicular lymphoma: a genetic perspective.

Authors:  Emilie Mamessier; Joo Y Song; Franziska C Eberle; Svetlana Pack; Charlotte Drevet; Bruno Chetaille; Ziedulla Abdullaev; José Adelaïde; Daniel Birnbaum; Max Chaffanet; Stefania Pittaluga; Sandrine Roulland; Andreas Chott; Elaine S Jaffe; Bertrand Nadel
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

6.  A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation.

Authors:  Alexios Matikas; Ifigeneia Tzannou; Dimitra Oikonomopoulou; Maria Bakiri
Journal:  BMJ Case Rep       Date:  2013-03-20

7.  Chronic myelogenous leukemia-like hematological malignancy with t(8;22) in a 26-year-old pregnant woman: A case report.

Authors:  You-Wen Qin; Yi-Ning Yang; Ping Bai; Chun Wang
Journal:  Oncol Lett       Date:  2016-04-27       Impact factor: 2.967

8.  Functional characterization of two rare BCR-FGFR1+ leukemias.

Authors:  Evan J Barnes; Jessica Leonard; Bruno C Medeiros; Brian J Druker; Cristina E Tognon
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-04-01

9.  Identification of a novel HOOK3-FGFR1 fusion gene involved in activation of the NF-kappaB pathway.

Authors:  Xuehong Zhang; Furong Wang; Fanzhi Yan; Dan Huang; Haina Wang; Beibei Gao; Yuan Gao; Zhijie Hou; Jiacheng Lou; Weiling Li; Jinsong Yan
Journal:  Cancer Cell Int       Date:  2022-01-26       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.